{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T16:32:17Z","timestamp":1780677137974,"version":"3.54.1"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Dotinurad is a novel selective urate transporter 1 (URAT1) inhibitor recently introduced in Japan. This study aims to evaluate the efficacy and safety of dotinurad in hyperuricemic patients with type 2 diabetic kidney disease by comparing serum levels of urate and plasma and urinary levels of indoxyl sulfate excreted via the urate excretion transporter ATP binding cassette subfamily G member 2 (ABCG2), as indices, with baseline levels after switching from febuxostat to dotinurad in hyperuricemic patients with type 2 diabetic kidney disease (DKD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this single-center, single-arm, open-label, prospective study, 37 hyperuricemic patients with DKD who had serum urate levels &amp;gt;6.0 mg\/dL despite at least 3 months of febuxostat 20 mg\/day were enrolled. Dotinurad was administered once daily for 24 weeks (starting at 0.5 mg\/day, titrated up to 4 mg\/day). The primary outcome was the proportion of patients achieving serum urate \u22646.0 mg\/dL at week 24. Secondary outcomes included changes in serum urate, plasma and urinary indoxyl sulfate levels, and safety parameters.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At week 24, 70.3% of patients (26\/37) achieved serum urate \u22646.0 mg\/dL, significantly exceeding the predefined threshold of 30% (p &amp;lt; 0.01). Serum uric acid levels transiently increased from baseline 4 weeks after switching (p&amp;lt;0.01), but decreased to a mean of 5.5 mg\/dL by 24 weeks (p&amp;lt;0.01). Urinary uric acid excretion increased significantly during the observation period, reflecting improved uric acid clearance. Urinary indoxyl sulfate (corrected for creatinine) showed significant increases at weeks 4 and 12, and indoxyl sulfate clearance was significantly improved at week 24. No clinically meaningful changes were observed in renal function, glycemic control, lipid profile, or blood pressure. Adverse events occurred in 17 patients (45.9%), mostly mild; two (5.4%) experienced serious events, with no drug-related safety concerns identified.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Switching to dotinurad was significantly reduced serum urate levels via URAT1 inhibition, potentially without adversely affecting ABCG2 function, with the majority of patients achieving the target urate level (\u22646.0 mg\/dL) by week 24. Including the absence of new safety concerns, dotinurad appears to be an effective urate-lowering therapy for patients with type 2 DKD.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1655502","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T17:49:17Z","timestamp":1759427357000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, may substantially reduce serum urate levels, through URAT1 inhibition, potentially without adversely affecting ABCG2 function: findings from the SWITCH SURI study"],"prefix":"10.3389","volume":"16","author":[{"given":"Takeshi","family":"Osonoi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Shirabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyoko","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Hosoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norie","family":"Watahiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satako","family":"Douguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Ofuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Katoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.14867\/gnamtsunyo.44.Supplement_sp-1","article-title":"Japanese society of gout and uric & nucleic acids 2019 guidelines for management of hyperuricemia and gout 3rd edition","volume":"44","author":"Hisatome","year":"2020","journal-title":"Gout Uric Nucleic Acids"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000249768.26560.66","article-title":"Serum uric acid predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study","volume":"48","author":"Mellen","year":"2006","journal-title":"Hypertension"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2015.11.003","article-title":"Serum uric acid: a strong and independent predictor of metabolic syndrome after adjusting for body composition","volume":"65","author":"Yu","year":"2016","journal-title":"Metabolism"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(04)00934-5","article-title":"Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort","volume":"44","author":"Iseki","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2337\/dc11-1346","article-title":"Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function","volume":"35","author":"Zoppini","year":"2012","journal-title":"Diabetes Care"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/art.20102","article-title":"Quality of care indicators for gout management","volume":"50","author":"Mikuls","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nature742","article-title":"Molecular identification of a renal urate anion exchanger that regulates blood urate levels","volume":"417","author":"Enomoto","year":"2002","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000427","article-title":"The systems biology of uric acid transporters: the role of remote sensing and signaling","volume":"27","author":"Nigam","year":"2018","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"B9","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/ncomms1756","article-title":"Decreased extra-renal urate excretion is a common cause of hyperuricemia","volume":"3","author":"Ichida","year":"2012","journal-title":"Nat Commun"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133817","article-title":"Gut-derived uremic toxin handling in vivo requires OAT-mediated tubular secretion in chronic kidney disease","volume":"5","author":"Bush","year":"2020","journal-title":"JCI Insight"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.005022","article-title":"Indoxyl sulfate: A novel cardiovascular risk factor in chronic kidney disease","volume":"6","author":"Hung","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2016.00518","article-title":"Identification of febuxostat as a new strong ABCG2 inhibitor: potential applications and risks in clinical situations","volume":"7","author":"Miyata","year":"2016","journal-title":"Front Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.259341","article-title":"Pharmacological evaluation of dotinurad, a selective urate reabsorption inhibitor","volume":"371","author":"Taniguchi","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10157-019-01818-2","article-title":"Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study","volume":"24","author":"Hosoya","year":"2020","journal-title":"Clin Exp Nephrol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1042061","article-title":"Efficacy and safety of switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, in hyperuricemic patients with type 2 diabetic kidney disease: Protocol for a single-arm, open-label, prospective, exploratory study","volume":"13","author":"Osonoi","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1038\/s41467-019-09735-4","article-title":"Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease","volume":"10","author":"Kikuchi","year":"2019","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2025.03.047","article-title":"Dotinurad treatment for patients with hyperuricemia complicating CKD","volume":"10","author":"Tanabe","year":"2025","journal-title":"Kidney Int Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.83332","article-title":"Changes in uric acid levels and effects on renal function after switching from febuxostat to dotinurad in patients with chronic kidney disease: A retrospective study","volume":"17","author":"Mima","year":"2025","journal-title":"Cureus"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1253\/circj.cj-14-0401","article-title":"Plasma indoxyl sulfate and estimated glomerular filtration rate","volume":"78","author":"Yoshikawa","year":"2014","journal-title":"Circ J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/s0272-6386(98)70067-8","article-title":"Regulation of renal urate excretion: A critical review","volume":"32","author":"Maesaka","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/art.1780080429","article-title":"Role of the intestinal tract in the elimination of uric acid","volume":"8","author":"Sorensen","year":"1965","journal-title":"Arthritis Rheum"},{"key":"B22","doi-asserted-by":"publisher","first-page":"5ra11","DOI":"10.1126\/scitranslmed.3000237","article-title":"Common defects of ABCG2, a high-capacity urate exporter, cause gout: A function-based genetic analysis in a Japanese population","volume":"1","author":"Matsuo","year":"2009","journal-title":"Sci Transl Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s10157-019-01831-5","article-title":"Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout","volume":"24","author":"Hosoya","year":"2020","journal-title":"Clin Exp Nephrol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key245","article-title":"Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout","volume":"58","author":"Terkeltaub","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2020.1784556","article-title":"Real-world treatment of gout and asymptomatic hyperuricemia: A cross-sectional study of Japanese health insurance claims data","volume":"31","author":"Koto","year":"2021","journal-title":"Modern Rheumatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2020.1784556","article-title":"Factors associated with achieving target serum uric acid level and occurrence of gouty arthritis: A retrospective observational study of Japanese health insurance claims data","volume":"30","author":"Koto","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/HPC.0000000000000388","article-title":"Hyperuricemia and cardiovascular risk: insights and implications","volume":"24","author":"Shubietah","year":"2025","journal-title":"Crit Pathw Cardiol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-019-01746-4","article-title":"A non\u2212inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout","volume":"24","author":"Hosoya","year":"2020","journal-title":"Clin Exp Nephrol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/art.42266","article-title":"Superiority of low-dose benzbromarone to low-dose febuxostat in a prospective, randomized comparative effectiveness trial in gout patients with renal uric acid underexcretion","volume":"74","author":"Yan","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"B31","unstructured":"Guideline for the Management of Hyperuricemia and Gout\n          \n          \n          Tokyo\n          Japanese Society of Gout and Nucleic Acid Metabolism\n          \n          2002"},{"key":"B32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2021.09.011","article-title":"Inequalities in enrollment of women and racial minorities in trials testing uric acid lowering drugs","volume":"31","author":"Fogacci","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1655502\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T17:49:19Z","timestamp":1759427359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1655502\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":33,"alternative-id":["10.3389\/fendo.2025.1655502"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1655502","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"article-number":"1655502"}}